iShares Biotechnology ETF (IBB)

I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.

Looking at the monthly chart, XRT now sits back in economic contraction, or below the 23-month moving average. 

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as volatility rises quickly?

Large cap biopharma and MedTech stocks are leading the healthcare sector higher.

On the weekly chart, IBB is breaking under the 200-week moving average. 

It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average. 

The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.

Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value

Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.

Zooming out to the weekly chart of TLT, we see a double bottom in play from the lows in October 2023 and January 2025. 

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds.

The major sector ETFs remain muted. Nothing screams wildly bullish or horribly bearish in the weekly charts. 

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Do you believe the economy is heading towards inflation? What about a recession? Are gold prices sending a warning? Read on for the answer.

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

The Federal debt in 1965 was $322.3 billion. In 2025 it is at $36.24 trillion. The unemployment rate was 5.2%. Now it is at 4.1%.

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

The technical aspect of DeepSeek is not new. The reaction to it though, is new. 

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Transportation IYT chart is incredible. The price action Friday showed the attempt to take out the January trend trade range and then failed.  

Sugar, as shown in the weekly chart, has broken down under the 200-WMA for the first time since December 2020. However, it is holding the August 2024 low.